Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
The authors appear unduly pessimistic about the currently available
contraceptive options. Progestogen only methods are particularly suitable
in women with congenital heart disease. Implanon has very good efficacy
and is particularly suitable for adolescents because there are no concerns
about bone density. In contrast Depoprovera may reduce oestradiol levels
and is no longer recomended as a first line method in young women. The
latest Progestogen only pill, Cerazette, inhibits ovulation and hopefully
will provide as effective in effiacy as the combined preparations (this
awaits demonstration in randomised trials).
The Mirena device has been an important advance but the newer copper
IUDs (inter uterine devices) which contain 380mm2 are nearly as effective
in efficacy terms and do not have the problems of irregular bleeding.
All of the long acting methods (Implanon, Mirena and copper IUDs) are
as good if not better than sterilisation at preventing pregnancy. They
avoid the surgical risks of the procedure and perhaps some of the
psycological problems asociated with sterilisation in young women who must
avoid pregnancy because of their medical condition.
Competing interests:
None declared
Competing interests:
No competing interests
18 February 2006
Gillian E Robinson
Associate Specialist Sexual and reproductive Health
Pregnancy and Congenital Heart Disease
The authors appear unduly pessimistic about the currently available
contraceptive options. Progestogen only methods are particularly suitable
in women with congenital heart disease. Implanon has very good efficacy
and is particularly suitable for adolescents because there are no concerns
about bone density. In contrast Depoprovera may reduce oestradiol levels
and is no longer recomended as a first line method in young women. The
latest Progestogen only pill, Cerazette, inhibits ovulation and hopefully
will provide as effective in effiacy as the combined preparations (this
awaits demonstration in randomised trials).
The Mirena device has been an important advance but the newer copper
IUDs (inter uterine devices) which contain 380mm2 are nearly as effective
in efficacy terms and do not have the problems of irregular bleeding.
All of the long acting methods (Implanon, Mirena and copper IUDs) are
as good if not better than sterilisation at preventing pregnancy. They
avoid the surgical risks of the procedure and perhaps some of the
psycological problems asociated with sterilisation in young women who must
avoid pregnancy because of their medical condition.
Competing interests:
None declared
Competing interests: No competing interests